Serum immunoglobulin a concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver

World Journal of Gastroenterology

Volumn 20, Issue 35, 2014, Pages 12566-12573

  Maleki, Iradj ^a   Aminafshari, Mahmood Reza ^a   Taghvaei, Tarang ^a   Hosseini, Vahid ^a   Rafiei, Alireza ^b   Torabizadeh, Zhila ^c   Barzin, Maryam ^c   Orang, Elahe ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biological markers; Fibrosis; Immunoglobulin A; Liver cirrhosis; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYMATIC ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; NONALCOHOLIC FATTY LIVER; SPECTROPHOTOMETER; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; AREA UNDER THE CURVE; BIOPSY; BLOOD; COMPLICATION; DISEASE COURSE; IMMUNOLOGY; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SEROLOGY; SEVERITY OF ILLNESS INDEX; UPREGULATION;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84909609696     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i35.12566     Document Type: Article

References (36)

1. Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G, Marra F, Pinzani M. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol 2009; 8: 89-94 [PMID: 19502649]
2. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010; 16: 4784-4791 [PMID: 20939106 DOI: 10.3748/wjg.v16.i38.4784]
3. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682-1698 [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077]
4. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52 [PMID: 15895401 DOI: 10.1002/hep.20734]
5. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16: 1087-1093 [PMID: 15489565 DOI: 10.1097/00042737-200411000-00002]
6. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis 2012; 16: 567-585 [PMID: 22824481 DOI: 10.1016/j.cld.2012.05.001]
7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
8. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011; 26 Suppl 1: 163-172 [PMID: 21199528 DOI: 10.1111/j.1440-1746.2010.06548.x]
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
10. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123 [PMID: 10833486 DOI: 10.1016/S0016-5085(00)70364-7]
11. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255-259 [PMID: 15633226]
12. Powell EE, Jonsson JR, Clouston AD. Dangerous liaisons: the metabolic syndrome and nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 753-754 [PMID: 16287799 DOI: 10.7326/0003-4819-143-10-200511150-00015]
13. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008; 34: 634-637 [PMID: 19195623 DOI: 10.1016/S1262-3636(08)74597-X]
14. Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30: 158-162 [PMID: 22722431 DOI: 10.1159/000336669]
15. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13 [PMID: 22418883 DOI: 10.1055/s-0032-1306421]
16. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317 [PMID: 19065650 DOI: 10.1002/hep.22603]
17. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-1437 [PMID: 18500507 DOI: 10.1007/s11695-008-9506-y]
18. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010; 51: 111-120 [PMID: 19885878 DOI: 10.1002/hep.23271]
19. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 Suppl 1: S34-S38 [PMID: 16540765]
20. Chave G, Milot L, Pilleul F. [Out of phase magnetic resonance imaging and liver applications]. J Radiol 2005; 86: 993-997 [PMID: 16224338 DOI: 10.1016/S0221-0363(05)81482-9]
21. Miller MH, Ferguson MA, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver Int 2011; 31: 461-473 [PMID: 21382157 DOI: 10.1111/j.1478-3231.2011.02451.x]
22. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-582 [PMID: 17653654 DOI: 10.1007/s00535-007-2060-x]
23. Maleki I, Rastgar A, Hosseini V, Taghvaei T, Rafiei A, Barzin M, Torabizadeh Z, Naghshvar F, Khalilian A. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease. Eur Rev for Med Pharmacol Sci 2014; 18: 1583-1590
24. Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163 [PMID: 11732005 DOI: 10.1053/jhep.2001.29628]
25. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589 [PMID: 17661414 DOI: 10.1002/hep.21768]
26. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844 [PMID: 17352011]
27. Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol 2005; 140: 478-490 [PMID: 15932509 DOI: 10.1111/j.1365-2249.2005.02779.x]
28. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, Fernandez-Merino C, Vidal C. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 2008; 151: 42-50 [PMID: 18005364 DOI: 10.1111/j.1365-2249.2007.03545.x]
29. Gonzàlez-Quintela A, Alende MR, Gamallo R, Gonzàlez-Gil P, López-Ben S, Tomé S, Otero E, Torre JA. Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease. Hepatogastroenterology 2003; 50: 2121-2126 [PMID: 14696478]
30. Tomita K, Teratani T, Yokoyama H, Suzuki T, Irie R, Ebinuma H, Saito H, Hokari R, Miura S, Hibi T. Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci 2011; 56: 3648-3654 [PMID: 21674175 DOI: 10.1007/s10620-011-1771-2]
31. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95: 755-760 [PMID: 23370710 DOI: 10.1097/TP.0b013e31827afb3a]
32. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59: 2188-2195 [PMID: 24375711 DOI: 10.1002/hep.26986]
33. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-823 [PMID: 22966992]
34. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007; 27: 378-387 [PMID: 17514501]
35. Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, Rigopoulou EI, Dalekos GN. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol 2008; 28: 501-511 [PMID: 18551357 DOI: 10.1007/S10875-008-9211-6]
36. Berglin L, Björkström NK, Bergquist A. Primary sclerosing cholangitis is associated with autoreactive IgA antibodies against biliary epithelial cells. Scand J Gastroenterol 2013; 48: 719-728 [PMID: 23713804 DOI: 10.3109/00365521]